Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806011 | 1.00 | APP (1.00) | APPMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL1804421 | 0.91 | APP (0.83) | APPMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL1804423 | 0.91 | APP (0.83) | APPMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL1810006 | 0.90 | APP (1.00) | APPMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL1810007 | 0.90 | APP (1.00) | APPMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL9727779 | 0.86 | APP (0.75) | APPMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL5828704 | 0.85 | APP (0.74) | APPMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL5828701 | 0.85 | APP (0.74) | APPMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL1808248 | 0.83 | APP (1.00) | APPMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL1808247 | 0.83 | APP (1.00) | APPMAPTALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124888-A1 | STYRYLBENZOFURAN DERIVATIVES AS INHIBITORS FOR BETA-AMYLOID FIBRIL FORMATION AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-26 | — | — | US | claimed |
| US-20110124888-A1 | STYRYLBENZOFURAN DERIVATIVES AS INHIBITORS FOR BETA-AMYLOID FIBRIL FORMATION AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124888-A1 | STYRYLBENZOFURAN DERIVATIVES AS INHIBITORS FOR BETA-AMYLOID FIBRIL FORMATION AND PREPARATION METHOD THEREOF | APP, BACE1, PSEN1 | APP 1/4885MAPT 7/4885ALDH1A1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.